(J Am Heart Assoc. 2017;6:e005608 DOI: [10.1161/JAHA.117.005608](10.1161/JAHA.117.005608).)28522676

This work was presented as an oral presentation at the Alzheimer\'s Association International Conference, July 22---27, 2016, in Toronto, Canada.

Clinical PerspectiveWhat Is New?Diffusion tensor imaging quantifies the microstructural integrity of white matter in the brain.Changes to brain white matter microstructural integrity provide an early indication of who is at risk of cerebral white matter injury and subsequent cognitive impairment.We found elevated glucose in midlife and elevated blood pressure at both midlife and late life were associated with worse brain white matter microstructural integrity. These associations were largely independent of the severity of white matter hyperintensities, a marker of cerebral white matter injury.Lipid levels at midlife or late life were not associated with brain white matter microstructural integrity.What Are the Clinical Implications?Avoiding elevated glucose in midlife and hypertension at any point may prevent later damage to brain white matter microstructural integrity and its downstream effects.Diffusion tensor imaging--based measures may be appropriate risk‐stratification tools or surrogate outcomes in clinical trials intervening with regard to vascular risk factors.Additional work is required to confirm these findings and to better establish the utility of these markers.

Introduction {#jah32249-sec-0008}
============

Vascular risk factors may increase the risk of subsequent cognitive decline and dementia, with the strongest evidence supporting a link between midlife vascular risk‐factor levels and late life cognition.[1](#jah32249-bib-0001){ref-type="ref"}, [2](#jah32249-bib-0002){ref-type="ref"}, [3](#jah32249-bib-0003){ref-type="ref"} In the absence of stroke, subclinical brain injury likely mediates these associations. Diffusion tensor imaging (DTI) quantifies the microstructural integrity of white matter (WM),[4](#jah32249-bib-0004){ref-type="ref"} which almost certainly plays a role in later life cognitive impairment,[5](#jah32249-bib-0005){ref-type="ref"}, [6](#jah32249-bib-0006){ref-type="ref"} and so can be used to assess subclinical brain injury. DTI also complements other neuroimaging measures, namely measures of WM hyperintensities (WMHs) or WM volumes, because it provides an assessment of pathologic changes that precede and predict the development of WMH or WM loss.[7](#jah32249-bib-0007){ref-type="ref"}, [8](#jah32249-bib-0008){ref-type="ref"}, [9](#jah32249-bib-0009){ref-type="ref"}, [10](#jah32249-bib-0010){ref-type="ref"}, [11](#jah32249-bib-0011){ref-type="ref"}, [12](#jah32249-bib-0012){ref-type="ref"} Consequently, changes to WM microstructural integrity provide an early indication of who is at risk of cerebral WM injury, including both WMH and WM loss, and subsequent cognitive impairment. Identifying risk factors for poor WM microstructural integrity will help us understand the extent to which DTI‐based measures are appropriate risk‐stratification tools or surrogate outcomes in clinical trials. As such, understanding risk factors for poor WM microstructural integrity will be critical in efforts to prevent or mitigate these adverse outcomes.

Given the link between measures of WM microstructural integrity and subsequent development of WMHs, we hypothesized that risk factors for poor WM microstructural integrity and WMHs would be similar. Elevated blood pressure is consistently associated with the presence, severity, and progression of WMH, regardless of the timing of measurement.[13](#jah32249-bib-0013){ref-type="ref"}, [14](#jah32249-bib-0014){ref-type="ref"}, [15](#jah32249-bib-0015){ref-type="ref"}, [16](#jah32249-bib-0016){ref-type="ref"}, [17](#jah32249-bib-0017){ref-type="ref"}, [18](#jah32249-bib-0018){ref-type="ref"} Although diabetes mellitus and fasting glucose are not typically associated with WMH in cross‐sectional analyses,[19](#jah32249-bib-0019){ref-type="ref"}, [20](#jah32249-bib-0020){ref-type="ref"} previous diabetes mellitus and fasting glucose are related to WMH progression and later WMH severity in longitudinal analyses.[16](#jah32249-bib-0016){ref-type="ref"}, [18](#jah32249-bib-0018){ref-type="ref"} Conversely, lipids do not appear to be associated with severity or progression of WMH.[16](#jah32249-bib-0016){ref-type="ref"}, [19](#jah32249-bib-0019){ref-type="ref"} In comparison, existing studies evaluating the association between these risk factors and WM microstructural integrity are typically small and cross‐sectional, and despite evidence of a link between WM microstructural integrity and WMH, most have not investigated whether the association is independent of or modified by WMH. The goal of this study was to quantify the association of midlife and late‐life measures of vascular risk factors with late‐life WM microstructural integrity in a relatively large sample of persons drawn from ARIC‐NCS (Atherosclerosis Risk in Communities Neurocognitive Study) and to consider whether the association is independent of or modified by WMH.

Methods {#jah32249-sec-0009}
=======

Study Population {#jah32249-sec-0010}
----------------

The ARIC study is a longitudinal cohort study of 15 792 persons recruited between 1987 and 1989 (visit 1) from 4 US communities: suburbs of Minneapolis, Minnesota; Forsyth County, North Carolina; Washington County, Maryland; and Jackson, Mississippi. In 2011--2013 (visit 5), all persons with evidence of cognitive impairment and a stratified random sample of other participants were invited to complete brain magnetic resonance imaging (MRI) as part of ARIC‐NCS.[21](#jah32249-bib-0021){ref-type="ref"} As such, although the MRI subsample is enriched with persons with cognitive impairment, use of derived sampling weights allows estimation of what the effects would be had we obtained MRI on all ARIC visit 5 participants. Our eligible sample included those ARIC‐NCS participants with valid DTI data, excluding nonblack and nonwhite persons (n=6), black participants from Maryland or Minnesota (n=9), persons disallowing the use of genetic data (n=10), and persons with prior stroke (n=66). Primary analyses also excluded persons missing exposure or covariate data; we considered associations in the full eligible sample after multiply imputing missing data in sensitivity analyses. The institutional review boards of all participating institutions approved this study, and participants provided written informed consent before participation.

Brain Imaging {#jah32249-sec-0011}
-------------

At ARIC‐NCS, each study site followed identical protocols for 3‐T brain MRI. All scans included sagittal T1‐weighted MPRAGE (magnetization‐prepared rapid gradient‐echo imaging), axial T2 FLAIR (fluid attenuation inversion recovery), and axial DTI pulse sequences. Data were processed by the ARIC MRI Reading Center at the Mayo Clinic (Rochester, MN). We provide an overview below (see Supplementary Methods for details).

Fractional anisotropy (FA) measures the directional constraint of water diffusion and ranges from 0 to 1 (unitless). Mean diffusivity (MD) is a scalar measure of how quickly water molecules diffuse overall (mm^2^/s). Lower FA and higher MD indicate worse WM microstructural integrity. WM FA and MD were calculated for brain regions defined by an in‐house atlas of lobar and deep WM regions based on the STAND400 template.[22](#jah32249-bib-0022){ref-type="ref"} The WM regions were intersected with tissue segmentations from each participant\'s T1‐weighted and FLAIR images; WM FA and MD were calculated using voxels with a \>50% probability of being WM. The segmentation takes care to include WMHs as WM. To account for imperfect registration between the DTI and T1‐weighted images, an upper cutoff of MD \<0.002 mm^2^/s was applied to exclude edge voxels that were primarily cerebrospinal fluid. We averaged left and right WM FA and MD across atlas regions and then took a weighted average, with weights based on the number of voxels in each WM region, to create WM FA and MD measures for 7 regions of interest (ROIs): frontal, temporal, occipital, and parietal lobes; anterior and posterior corpus callosum; and an overall measure---the weighted average of these 6 ROIs (capsular WM was not included). WMH and intracranial volumes were quantified via in‐house algorithms.[23](#jah32249-bib-0023){ref-type="ref"}, [24](#jah32249-bib-0024){ref-type="ref"}

Vascular Risk Factors {#jah32249-sec-0012}
---------------------

We considered vascular risk factors at ARIC visit 1 (1987--1989, midlife, ages 44--65) and ARIC visit 5 (2011--2013, late life, ages 67--90). Plasma total cholesterol and triglycerides were measured using enzymatic methods,[25](#jah32249-bib-0025){ref-type="ref"}, [26](#jah32249-bib-0026){ref-type="ref"} high‐density lipoprotein cholesterol (HDL‐C) concentrations were determined after precipitation of non‐HDL lipoproteins,[27](#jah32249-bib-0027){ref-type="ref"}, [28](#jah32249-bib-0028){ref-type="ref"} and low‐density lipoprotein cholesterol (LDL‐C) levels were calculated using the Friedewald equation.[29](#jah32249-bib-0029){ref-type="ref"} Serum glucose was measured using the hexokinase method.[30](#jah32249-bib-0030){ref-type="ref"} Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured 3 times according to a standard protocol; we consider the mean of the 2 final measurements.

Covariates {#jah32249-sec-0013}
----------

All covariates are based on data collected at ARIC visit 1 or at ARIC visit 5 and include age (years), sex (male, female), race and center (black--Mississippi, black--North Carolina, white--North Carolina, white--Maryland, white--Minnesota), education (less than high school/high school, General Educational Development test, vocational school, some college/college, graduate or professional school), *APOE\*E4* allele status (present, absent), body mass index (kg/m^2^), smoking status (current, former, never), antihypertensive medication use (yes, no), lipid‐lowering medication use (yes, no), and diabetes mellitus medication use (yes, no). Medication use was determined through direct visual inspection and linkage to Medi‐Span therapeutic classification codes.

Statistical Methods {#jah32249-sec-0014}
-------------------

We standardized ROI WM FA and MD by subtracting the sample mean and dividing by the sample standard deviation. For our primary analyses, we used separate weighted linear regression models to quantify the association between each vascular risk factor and WM FA and MD in each ROI. The weights account for the approach used to select ARIC participants for MRI. Given slight deviations from a linear dose‐response pattern for some exposures in exploratory analyses, we considered associations with both categorical and linear exposure parameterizations. All analyses were adjusted for the covariates described above and the other vascular risk factors (eg, SBP, DBP, and glucose in models estimating associations with lipids). Time‐varying covariates were updated to reflect the status at the time of exposure assessment (eg, visit 1 age when considering visit 1 SBP, visit 5 age for visit 5 SBP). We then adjusted these primary models for total WMH volumes and intracranial volume to determine whether our associations were independent of WMH severity.

We conducted several sensitivity analyses. We repeated analyses considering glucose and lipids after restricting those who were fasting ≥8 hours at blood draw (98% at visit 1, 96% at visit 5). We repeated analyses for glucose and blood pressure adjusting for total cholesterol, HDL‐C, and triglycerides rather than LDL‐C. We restricted analyses of triglycerides to those with \<500 mg/dL triglycerides to exclude potentially influential outliers. We considered analyses after multiply imputing missing exposure and covariate data[31](#jah32249-bib-0031){ref-type="ref"} to understand the influence and missing data. Finally, we considered unweighted analyses to understand the influence of the selection process by which we selected visit 5 participants for MRI and analyses additionally weighted with inverse probability of attrition weights[32](#jah32249-bib-0032){ref-type="ref"}, [33](#jah32249-bib-0033){ref-type="ref"} to better understand the potential influence of potentially informative attrition from visit 1 to visit 5 on our results.

We used multiplicative interaction terms to evaluate effect modification by age (\<75 or ≥75 years), race (black or white), sex (male or female), *APOE\*E4* (present or absent), cognitive status (normal/mild cognitive impairment or dementia), and WMH severity (deciles of intracranial volume‐standardized WMH volumes). We considered *P*\<0.05 to be statistically significant and reported 95% confidence intervals. We did not adjust for multiple comparisons, given that the association between a vascular risk factor at a given time point and 1 measure of WM microstructural integrity is likely correlated with associations considering other time points or ROIs. All analyses were completed using SAS version 9.4, STATA version 14.0, or R version 3.1.2.

Results {#jah32249-sec-0015}
=======

Weighted characteristics of the 1851 eligible persons are provided in [Table](#jah32249-tbl-0001){ref-type="table-wrap"}. Mean SBP and glucose were higher at visit 5 than at visit 1, whereas mean DBP, total cholesterol, and LDL‐C were lower. Tables [S1](#jah32249-sup-0001){ref-type="supplementary-material"} and [S2](#jah32249-sup-0001){ref-type="supplementary-material"} provide unweighted summary statistics and information on missingness.

###### 

Weighted Characteristics of Eligible ARIC‐NCS Participants at Visits 1 and 5 (n=1851)

                                                Visit 1 (1987--1989)   Visit 5 (2011--2013)   *P* Value[b](#jah32249-note-0005){ref-type="fn"}
  --------------------------------------------- ---------------------- ---------------------- --------------------------------------------------
  Time to MRI, y                                23.6 (23.0, 24.2)      0 (0, 0)               ···
  Age, y                                        51.7 (46.8, 55.1)      75.3 (70.4, 78.7)      \<0.0001
  Cognitively normal                            ···                    74.1%                  ···
  *APOE\*E4* allele                             27.4%                  ···                    
  Male                                          38.5%                  ···                    
  Race‐center                                                          ···                    
  White‐Minnesota                               29.9%                                         
  White‐Maryland                                27.6%                                         
  White‐North Carolina                          21.2%                                         
  Black‐North Carolina                          1.7%                                          
  Black‐Mississippi                             19.6%                                         
  Education                                                            ···                    
  \<12 y                                        11.8%                                         
  12--16 y                                      40.3%                                         
  \>16 y                                        47.9%                                         
  Smoking status                                                       \<0.0001               
  Current                                       16.6%                  5.2%                   
  Former                                        33.2%                  51.6%                  
  Never                                         50.2%                  43.1%                  
  Body mass index, kg/m^2^                      26.8 (23.3, 29.3)      28.4 (24.7, 31.2)      \<0.0001
  Systolic blood pressure, mm Hg                114.8 (103.7, 122.9)   129.8 (117.1, 140.1)   \<0.0001
  Diastolic blood pressure, mm Hg               72.2 (64.7, 78.0)      66.0 (58.6, 72.3)      \<0.0001
  Fasting glucose, mg/dL                        99.4 (90.9, 102.8)     112.0 (96.9, 117.2)    \<0.0001
  Total cholesterol, mg/dL                      209.6 (182.0, 231.2)   185.9 (155.2, 212.4)   \<0.0001
  HDL‐C, mg/dL                                  54.2 (42.0, 63.1)      53.4 (43.0, 61.6)      0.007
  LDL‐C, mg/dL                                  132.2 (107.5, 154.5)   107.4 (81.3, 128.3)    \<0.0001
  Triglycerides, mg/dL                          117.3 (71.3, 139.8)    125.7 (85.2, 147.9)    \<0.0001
  Antihypertensive medication use               20.2%                  72.6%                  \<0.0001
  Medication use for diabetes mellitus          1.7%                   18.5%                  \<0.0001
  Lipid‐lowering medication use                 1.6%                   51.9%                  \<0.0001
  Hypercholesterolemia                          57.3%                  34.9%                  \<0.0001
  Fractional anisotropy, by region                                                            
  Frontal                                       ···                    0.28 (0.27, 0.30)      ···
  Temporal                                      ···                    0.28 (0.27, 0.30)      ···
  Parietal                                      ···                    0.30 (0.29, 0.31)      ···
  Occipital                                     ···                    0.22 (0.20, 0.24)      ···
  Anterior corpus callosum                      ···                    0.43 (0.39, 0.47)      ···
  Posterior corpus callosum                     ···                    0.58 (0.54, 0.62)      ···
  Overall                                       ···                    0.28 (0.27, 0.30)      ···
  Mean diffusivity, by region, 10^−4^ mm^2^/s                                                 
  Frontal                                       ···                    8.5 (8.2, 8.9)         ···
  Temporal                                      ···                    8.8 (8.4, 9.2)         ···
  Parietal                                      ···                    8.8 (8.3, 9.1)         ···
  Occipital                                     ···                    8.7 (8.2, 9.1)         ···
  Anterior corpus callosum                      ···                    11.5 (10.7, 12.2)      ···
  Posterior corpus callosum                     ···                    11.2 (10.4, 11.8)      ···
  Overall                                       ···                    8.7 (8.3, 9.1)         ···

ARIC‐NCS indicates Atherosclerosis Risk in Communities Neurocognitive Study; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; MRI, magnetic resonance imaging.

Summary measures among those with data for a given variable.

Comparing visits 1 and 5 using a weighted paired *t* test or McNemar test, as appropriate.

Findings were generally consistent across ROIs, sensitivity analyses, and categorical and linear versions of the exposures (Figures [S1](#jah32249-sup-0001){ref-type="supplementary-material"} through [S28](#jah32249-sup-0001){ref-type="supplementary-material"}; Tables [S3](#jah32249-sup-0001){ref-type="supplementary-material"} through [S5](#jah32249-sup-0001){ref-type="supplementary-material"}). We reported the linear association between our vascular risk factors and overall WM MD or FA in the next sections and discussed other analyses only when they differed substantially from these analyses. Likewise, we discussed effect measure modification by age, sex, or race only when there was evidence supporting its presence.

Plasma Lipids {#jah32249-sec-0016}
-------------

Although there was little support for an adverse association between elevated lipids at visit 1 and overall WM FA, elevated total cholesterol, LDL‐C, and HDL‐C at visit 5 appeared to be associated with better overall WM FA (Figure [1](#jah32249-fig-0001){ref-type="fig"}). However, these protective associations were limited to those who remained cognitively normal at visit 5 (interaction *P*\<0.05, with the exception of *P*=0.08 for visit 5 HDL‐C) and were attenuated in sensitivity analyses omitting sampling weights or weighting for attrition, which upweight persons with cognitive impairment (Figures [S6](#jah32249-sup-0001){ref-type="supplementary-material"}, [S10](#jah32249-sup-0001){ref-type="supplementary-material"}, and [S14](#jah32249-sup-0001){ref-type="supplementary-material"}). Findings were materially unchanged after adjustment for WMH (Figure [1](#jah32249-fig-0001){ref-type="fig"}), and there was little support for effect modification by WMH volumes (Figures [S29](#jah32249-sup-0001){ref-type="supplementary-material"} through [S32](#jah32249-sup-0001){ref-type="supplementary-material"}). Analyses considering effect modification suggested an association between higher visit 5 triglycerides and worse overall FA in women but not men (interaction *P*=0.004).

![Comparison of primary and WMH‐adjusted analyses of the association of mid‐ or late‐life cardiovascular risk factors with overall WM FA. CI indicates confidence interval; DBP, diastolic blood pressure; FA, fractional anisotropy; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; WM, white matter; WMH, white matter hyperintensity.](JAH3-6-e005608-g001){#jah32249-fig-0001}

Visit 1 and 5 plasma lipids were not associated with overall WM MD, with the exception of an adverse association with elevated triglycerides at visit 5 (Figure [2](#jah32249-fig-0002){ref-type="fig"}); however, this result was not robust to sensitivity analyses omitting sampling weights or imputing missing data (Figure [S4](#jah32249-sup-0001){ref-type="supplementary-material"}). Adjustment for WMH did not alter these findings (Figure [2](#jah32249-fig-0002){ref-type="fig"}). Some evidence suggested an association between elevated LDL‐C and worse overall WM FA and MD only in those in the highest decile of standardized WMH volumes (Figure [S30](#jah32249-sup-0001){ref-type="supplementary-material"}). Analyses considering effect modification also suggested a protective association between visit 1 HDL‐C and overall WM MD in black but not white participants (interaction *P*=0.01).

![Comparison of primary and WMH‐adjusted analyses of the association of mid‐ or late‐life cardiovascular risk factors with overall WM MD. CI indicates confidence interval; DBP, diastolic blood pressure; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol; MD, mean diffusivity; SBP, systolic blood pressure; WM, white matter; WMH, white matter hyperintensity.](JAH3-6-e005608-g002){#jah32249-fig-0002}

Serum Glucose {#jah32249-sec-0017}
-------------

Elevated serum glucose at visit 1 was strongly associated with worse overall WM MD (Figure [2](#jah32249-fig-0002){ref-type="fig"}). Although elevated glucose at visit 1 was marginally associated with worse overall WM FA (Figure [1](#jah32249-fig-0001){ref-type="fig"}), analyses considering categories of glucose did not support an association (Table [S4](#jah32249-sup-0001){ref-type="supplementary-material"}). Visit 5 glucose was not associated with overall WM FA or MD, except in sensitivity analyses implementing inverse probability of attrition weighting, where higher visit 5 glucose was associated with worse overall WM MD. Results were similar after additional adjustment for WMH (Figures [1](#jah32249-fig-0001){ref-type="fig"} and [2](#jah32249-fig-0002){ref-type="fig"}), and the adverse association between elevated visit 1 glucose and worse MD or FA was stronger in those with the least WMH (Figures [3](#jah32249-fig-0003){ref-type="fig"} and [4](#jah32249-fig-0004){ref-type="fig"}).

![The adjusted association between cardiovascular risk factors at visit 1 or 5 and measures of overall white matter fractional anisotropy by decile of intracranial‐volume standardized WMH volumes. CI indicates confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure; WMH, white matter hyperintensity.](JAH3-6-e005608-g003){#jah32249-fig-0003}

![The adjusted association between cardiovascular risk factors at visit 1 or 5 and measures of overall white matter mean diffusivity by decile of intracranial‐volume standardized WMH volumes. CI indicates confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure; WMH, white matter hyperintensity.](JAH3-6-e005608-g004){#jah32249-fig-0004}

Blood Pressure {#jah32249-sec-0018}
--------------

Elevated SBP and DBP at either visit were strongly associated with worse overall WM FA and MD. Additional adjustment for WMH slightly attenuated, but did not eliminate, these associations (Figures [1](#jah32249-fig-0001){ref-type="fig"} and [2](#jah32249-fig-0002){ref-type="fig"}). There was little support for effect modification by WMH volumes (Figures [3](#jah32249-fig-0003){ref-type="fig"} and [4](#jah32249-fig-0004){ref-type="fig"}). Of note, in ROI‐specific analyses, associations with MD or FA in the anterior or posterior corpus callosum were often weaker or null, and the association between visit 1 DBP and MD was attenuated slightly in inverse probability of attrition weighting sensitivity analyses (Figures [S21](#jah32249-sup-0001){ref-type="supplementary-material"} through [S28](#jah32249-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah32249-sec-0019}
==========

To our knowledge, this study of the relation of vascular risk factors and WM microstructural integrity is the largest and most comprehensive to date. Consistent with our own findings that elevated blood pressure at both midlife and late life was associated with worse WM microstructural integrity, several small cross‐sectional studies also previously reported an association between elevated blood pressure and worse WM microstructural integrity.[7](#jah32249-bib-0007){ref-type="ref"}, [34](#jah32249-bib-0034){ref-type="ref"}, [35](#jah32249-bib-0035){ref-type="ref"}, [36](#jah32249-bib-0036){ref-type="ref"}, [37](#jah32249-bib-0037){ref-type="ref"}, [38](#jah32249-bib-0038){ref-type="ref"}, [39](#jah32249-bib-0039){ref-type="ref"}, [40](#jah32249-bib-0040){ref-type="ref"}, [41](#jah32249-bib-0041){ref-type="ref"}, [42](#jah32249-bib-0042){ref-type="ref"} Our finding of an association between midlife glucose and late‐life WM microstructural integrity is also consistent with 1 prior report of stronger associations between diabetes mellitus and WM microstructural integrity with increasing duration of diabetes mellitus.[43](#jah32249-bib-0043){ref-type="ref"} Although we did not observe a cross‐sectional association between glucose and WM microstructural integrity, prior cross‐sectional studies generally reported worse microstructural integrity in participants with diabetes mellitus compared with controls.[43](#jah32249-bib-0043){ref-type="ref"}, [44](#jah32249-bib-0044){ref-type="ref"}, [45](#jah32249-bib-0045){ref-type="ref"}, [46](#jah32249-bib-0046){ref-type="ref"}, [47](#jah32249-bib-0047){ref-type="ref"}, [48](#jah32249-bib-0048){ref-type="ref"} Given that these studies were modest in size (n\<250), focused on diabetes mellitus rather than glucose, and often reported effects only in localized brain regions, further work will be needed to reconcile these findings with our own. Finally, although we found little support for an adverse association between elevated lipids and late‐life WM microstructural integrity, prior reports are mixed, with studies reporting both null and adverse associations between lipids and WM microstructural integrity.[47](#jah32249-bib-0047){ref-type="ref"}, [49](#jah32249-bib-0049){ref-type="ref"}, [50](#jah32249-bib-0050){ref-type="ref"}, [51](#jah32249-bib-0051){ref-type="ref"} As with the literature on diabetes mellitus and WM microstructural integrity, however, these studies frequently report localized effects, which may not be reflected in our analyses, given our focus on large ROIs, and are limited by their size (n\<250). Our finding that associations between vascular risk factors and WM microstructural integrity were largely independent of WMH volumes is also consistent with some prior reports,[43](#jah32249-bib-0043){ref-type="ref"}, [45](#jah32249-bib-0045){ref-type="ref"}, [47](#jah32249-bib-0047){ref-type="ref"} reinforcing the notion that WM microstructural integrity damage likely precedes WMH.

Our findings underscore the importance of moving to longitudinal designs that can answer questions about when exposures are relevant. Strengths of this study include the large number participants, the use of data on midlife and late‐life vascular risk factors, and a community‐based sample. Compared with a voxelwise comparison‐based approach, our ROI‐based approach has a reduced chance of type I error and greater reproducibility but is unlikely to identify localized effects. Because we based our study on an MRI subsample, selection bias is a potential concern; however, we do not believe that this is a significant source of bias in this study because our sensitivity analyses designed to address and quantify this source of bias were generally consistent with our primary analyses. Other limitations include the lack of serial MRIs, precluding assessment change in FA or MD, and the potential for chance findings or residual bias.

Changes to WM microstructural integrity provide an early indication of who is at risk of cerebral WM injury, including both WMH and WM loss, and subsequent cognitive impairment. Our study confirmed that the risk factors for WM microstructural integrity and WMH are similar, and that, perhaps most important, these associations were independent of WMH presence and severity. Although our study provides early evidence to suggest that DTI‐based measures may be appropriate outcomes risk‐stratification tools or surrogate outcomes in clinical trials intervening with regard to vascular risk factors, additional work is required to confirm these findings and to better establish the utility of these markers. Regardless, our study suggests that avoiding elevated glucose in midlife and hypertension at any point may prevent later damage to WM microstructural integrity and its downstream effects.
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**Figure S10.** Comparison of the primary analyses of the association of high‐density lipoprotein cholesterol with regional and total fractional anisotropy with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S11.** Comparison of the primary analyses of the association of high‐density lipoprotein cholesterol with regional and total mean diffusivity with sensitivity analyses considering different adjustment sets.

**Figure S12.** Comparison of the primary analyses of the association of high‐density lipoprotein cholesterol with regional and total mean diffusivity with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S13.** Comparison of the primary analyses of the association of total cholesterol with regional and total fractional anisotropy with sensitivity analyses considering different adjustment sets.

**Figure S14.** Comparison of the primary analyses of the association of total cholesterol with regional and total fractional anisotropy with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S15.** Comparison of the primary analyses of the association of total cholesterol with regional and total mean diffusivity with sensitivity analyses considering different adjustment sets.

**Figure S16.** Comparison of the primary analyses of the association of total cholesterol with regional and total mean diffusivity with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S17.** Comparison of the primary analyses of the association of glucose with regional and total fractional anisotropy with sensitivity analyses considering different adjustment sets.

**Figure S18.** Comparison of the primary analyses of the association of glucose with regional and total fractional anisotropy with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S19.** Comparison of the primary analyses of the association of glucose with regional and total mean diffusivity with sensitivity analyses considering different adjustment sets.

**Figure S20.** Comparison of the primary analyses of the association of glucose with regional and total mean diffusivity with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S21.** Comparison of the primary analyses of the association of diastolic blood pressure with regional and total fractional anisotropy with sensitivity analyses considering different adjustment sets.

**Figure S22.** Comparison of the primary analyses of the association of diastolic blood pressure with regional and total fractional anisotropy with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S23.** Comparison of the primary analyses of the association of diastolic blood pressure with regional and total mean diffusivity with sensitivity analyses considering different adjustment sets.

**Figure S24.** Comparison of the primary analyses of the association of diastolic blood pressure with regional and total mean diffusivity with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S25.** Comparison of the primary analyses of the association of systolic blood pressure with regional and total fractional anisotropy with sensitivity analyses considering different adjustment sets.

**Figure S26.** Comparison of the primary analyses of the association of systolic blood pressure with regional and total fractional anisotropy with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S27.** Comparison of the primary analyses of the association of systolic blood pressure with regional and total mean diffusivity with sensitivity analyses considering different adjustment sets.

**Figure S28.** Comparison of the primary analyses of the association of systolic blood pressure with regional and total mean diffusivity with sensitivity analyses considering the influence of weighting, attrition, or missing covariate or exposure data.

**Figure S29.** The adjusted association between triglycerides at visit 1 or 5 and measures of total white matter integrity by decile of intracranial‐volume standardized white matter hyperintensity volumes.

**Figure S30.** The adjusted association between low‐density lipoprotein cholesterol at visit 1 or 5 and measures of white matter integrity by decile of intracranial‐volume standardized white matter hyperintensity volumes.

**Figure S31.** The adjusted association between high‐density lipoprotein cholesterol at visit 1 or 5 and measures of white matter integrity by decile of intracranial‐volume standardized white matter hyperintensity volumes.

**Figure S32.** The adjusted association between total cholesterol at visit 1 or 5 and measures of white matter integrity by decile of intracranial‐volume standardized white matter hyperintensity volumes.
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